Log In
BCIQ
Print this Print this
 

rociletinib (AVL-301) (formerly CO-1686)

  Manage Alerts
Collapse Summary General Information
Company Celgene Corp.
DescriptionSmall molecule that inhibits the T790M EGFR mutation and the initial activating EGFR mutations
Molecular Target Epidermal growth factor receptor (EGFR)
Mechanism of ActionEpidermal growth factor (EGF) receptor inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentRegistration
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsTreat non-small cell lung cancer (NSCLC); Treat non-small cell lung cancer (NSCLC) in patients with the T790M EGFR resistance mutation
Regulatory Designation U.S. - Breakthrough Therapy (Treat non-small cell lung cancer (NSCLC) in patients with the T790M EGFR resistance mutation);
U.S. - Priority Review (Treat non-small cell lung cancer (NSCLC));
U.S. - Priority Review (Treat non-small cell lung cancer (NSCLC) in patients with the T790M EGFR resistance mutation);
EU - Accelerated Assessment (Treat non-small cell lung cancer (NSCLC) in patients with the T790M EGFR resistance mutation);
EU - Accelerated Assessment (Treat non-small cell lung cancer (NSCLC))
PartnerClovis Oncology Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

5

$209.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today